Syros Pharmaceut Financials
This page shows Syros Pharmaceut (SYRS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2023 annual data. Scores normalized against common benchmarks. How we calculate these scores
Syros Pharmaceut has an operating margin of -1298.2%, meaning the company retains $-1298 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -913.1% the prior year.
Syros Pharmaceut's revenue declined 33.2% year-over-year, from $14.9M to $9.9M. This contraction results in a growth score of 0/100.
Syros Pharmaceut has a moderate D/E ratio of 2.07. This balance of debt and equity financing earns a leverage score of 34/100.
With a current ratio of 3.95, Syros Pharmaceut holds $3.95 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Syros Pharmaceut generated -$109.7M in operating cash flow, capex of $272K consumed most of it, leaving -$110.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Syros Pharmaceut passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Syros Pharmaceut generates $0.67 in operating cash flow (-$109.7M OCF vs -$164.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Syros Pharmaceut earns $-25.2 in operating income for every $1 of interest expense (-$129.0M vs $5.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Syros Pharmaceut generated $9.9M in revenue in fiscal year 2023. This represents a decrease of 33.2% from the prior year.
Syros Pharmaceut's EBITDA was -$126.7M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4.8% from the prior year.
Syros Pharmaceut generated -$110.0M in free cash flow in fiscal year 2023, representing cash available after capex. This represents an increase of 11.5% from the prior year.
Syros Pharmaceut reported -$164.6M in net income in fiscal year 2023. This represents a decrease of 73.9% from the prior year.
Syros Pharmaceut earned $-5.81 per diluted share (EPS) in fiscal year 2023. This represents an increase of 22.4% from the prior year.
Syros Pharmaceut held $139.5M in cash against $34.6M in long-term debt as of fiscal year 2023.
Syros Pharmaceut had 26M shares outstanding in fiscal year 2023. This represents an increase of 30.5% from the prior year.
Syros Pharmaceut's operating margin was -1298.2% in fiscal year 2023, reflecting core business profitability. This is down 385.1 percentage points from the prior year.
Syros Pharmaceut's net profit margin was -1656.3% in fiscal year 2023, showing the share of revenue converted to profit. This is down 1020.2 percentage points from the prior year.
Syros Pharmaceut invested $108.2M in research and development in fiscal year 2023. This represents a decrease of 3.4% from the prior year.
Syros Pharmaceut invested $272K in capex in fiscal year 2023, funding long-term assets and infrastructure. This represents a decrease of 78.1% from the prior year.
SYRS Income Statement
| Metric | Q3'24 | Q2'24 | Q1'24 | Q4'22 | Q3'23 | Q2'23 | Q1'23 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $387K-86.3% | $2.8M-4.1% | $3.0M | N/A | $3.9M-38.0% | $6.3M+14.8% | $5.5M-29.9% | $7.8M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $20.5M-6.5% | $22.0M-11.0% | $24.7M | N/A | $25.8M-22.2% | $33.1M+31.5% | $25.2M-6.1% | $26.8M |
| SG&A Expenses | $5.7M+3.5% | $5.5M-12.8% | $6.3M | N/A | $8.1M+16.3% | $6.9M-0.1% | $6.9M+8.1% | $6.4M |
| Operating Income | -$26.2M+4.5% | -$27.4M+11.3% | -$30.9M | N/A | -$39.5M-16.8% | -$33.8M-26.7% | -$26.7M-4.8% | -$25.4M |
| Interest Expense | $1.3M-5.1% | $1.4M+5.7% | $1.3M | N/A | $1.1M+7.1% | $981K+0.5% | $976K-1.1% | $987K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$6.4M+72.6% | -$23.3M-529.1% | -$3.7M | N/A | -$30.3M+12.3% | -$34.5M-37.1% | -$25.1M-5.6% | -$23.8M |
| EPS (Diluted) | $-0.16+72.9% | $-0.59-490.0% | $-0.10 | N/A | $-3.21 | $-5.40-35.3% | $-3.99 | N/A |
SYRS Balance Sheet
| Metric | Q3'24 | Q2'24 | Q1'24 | Q4'22 | Q3'23 | Q2'23 | Q1'23 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $85.0M-20.4% | $106.7M-20.8% | $134.7M-44.9% | $244.5M-14.1% | $284.7M+125.6% | $126.2M-17.0% | $152.1M-16.9% | $182.9M |
| Current Assets | $63.9M-24.7% | $84.9M-24.3% | $112.2M-46.9% | $211.4M-16.2% | $252.3M+174.4% | $91.9M-21.1% | $116.5M-14.7% | $136.6M |
| Cash & Equivalents | $58.3M-26.2% | $79.0M-5.5% | $83.5M-50.1% | $167.5M-2.4% | $171.5M+190.4% | $59.1M-15.1% | $69.6M-24.6% | $92.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $96.1M-15.0% | $113.1M-5.5% | $119.7M+2.5% | $116.8M-24.9% | $155.6M+63.4% | $95.2M+6.6% | $89.3M-8.6% | $97.7M |
| Current Liabilities | $28.4M+15.8% | $24.5M-34.3% | $37.3M+21.2% | $30.8M-19.9% | $38.4M-1.3% | $38.9M+41.1% | $27.6M-12.4% | $31.5M |
| Long-Term Debt | $41.1M+0.4% | $40.9M+37.8% | $29.7M-26.9% | $40.6M+0.3% | $40.5M+19.3% | $34.0M-12.4% | $38.8M-3.7% | $40.3M |
| Total Equity | -$11.1M-75.1% | -$6.4M-142.2% | $15.1M-88.2% | $127.7M-1.1% | $129.2M+316.4% | $31.0M-50.6% | $62.7M-26.4% | $85.2M |
| Retained Earnings | -$756.2M-0.9% | -$749.8M-3.2% | -$726.5M-30.1% | -$558.2M-0.9% | -$553.5M-5.8% | -$523.2M-7.1% | -$488.7M-5.4% | -$463.6M |
SYRS Cash Flow Statement
| Metric | Q3'24 | Q2'24 | Q1'24 | Q4'22 | Q3'23 | Q2'23 | Q1'23 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$20.7M+30.3% | -$29.7M+4.6% | -$31.1M0.0% | -$31.1M+13.1% | -$35.8M-36.7% | -$26.2M+12.8% | -$30.0M-30.7% | -$23.0M |
| Capital Expenditures | $38K+3900.0% | -$1K-100.4% | $235K-65.1% | $674K+105.5% | $328K+195.5% | $111K-13.3% | $128K-47.8% | $245K |
| Free Cash Flow | -$18.6M+16.9% | -$22.4M+39.7% | -$37.1M-16.9% | -$31.8M+12.1% | -$36.1M-37.4% | -$26.3M+12.8% | -$30.1M-29.9% | -$23.2M |
| Investing Cash Flow | $0-100.0% | $25.1M+201.7% | -$24.6M-165.3% | $37.7M+509.2% | $6.2M-61.0% | $15.9M+115.2% | $7.4M+3113.5% | -$245K |
| Financing Cash Flow | $0-100.0% | $41K+115.5% | -$265K+97.5% | -$10.7M-107.5% | $142.1M+63805.8% | -$223K-139.8% | -$93K-196.9% | $96K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SYRS Financial Ratios
| Metric | Q3'24 | Q2'24 | Q1'24 | Q4'22 | Q3'23 | Q2'23 | Q1'23 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -7012.9%-5812.8pp | -1200.1%-75.8pp | -1124.3% | N/A | -1014.0%-475.9pp | -538.1%-50.5pp | -487.5%-161.7pp | -325.9% |
| Net Margin | -16636.7%-15356.8pp | -1279.8%-474.5pp | -805.3% | N/A | -777.5%-228.1pp | -549.4%-89.5pp | -460.0%-154.7pp | -305.2% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -7.5%+14.3pp | -21.9%-19.1pp | -2.8% | N/A | -10.6%+16.7pp | -27.3%-10.8pp | -16.5%-3.5pp | -13.0% |
| Current Ratio | 2.25-1.2 | 3.46+0.5 | 3.01-3.9 | 6.87+0.3 | 6.57+4.2 | 2.36-1.9 | 4.22-0.1 | 4.33 |
| Debt-to-Equity | -3.69+2.8 | -6.44-8.4 | 1.97+1.7 | 0.320.0 | 0.31-0.8 | 1.10+0.5 | 0.62+0.1 | 0.47 |
| FCF Margin | -4806.2%-4016.0pp | -790.2%+466.9pp | -1257.1% | N/A | -928.2%-509.3pp | -418.9%+132.5pp | -551.4%-253.9pp | -297.5% |
Similar Companies
Frequently Asked Questions
What is Syros Pharmaceut's annual revenue?
Syros Pharmaceut (SYRS) reported $9.9M in total revenue for fiscal year 2023. This represents a -33.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Syros Pharmaceut's revenue growing?
Syros Pharmaceut (SYRS) revenue declined by 33.2% year-over-year, from $14.9M to $9.9M in fiscal year 2023.
Is Syros Pharmaceut profitable?
No, Syros Pharmaceut (SYRS) reported a net income of -$164.6M in fiscal year 2023, with a net profit margin of -1656.3%.
What is Syros Pharmaceut's earnings per share (EPS)?
Syros Pharmaceut (SYRS) reported diluted earnings per share of $-5.81 for fiscal year 2023. This represents a 22.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Syros Pharmaceut's EBITDA?
Syros Pharmaceut (SYRS) had EBITDA of -$126.7M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Syros Pharmaceut have?
As of fiscal year 2023, Syros Pharmaceut (SYRS) had $139.5M in cash and equivalents against $34.6M in long-term debt.
What is Syros Pharmaceut's operating margin?
Syros Pharmaceut (SYRS) had an operating margin of -1298.2% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.
What is Syros Pharmaceut's net profit margin?
Syros Pharmaceut (SYRS) had a net profit margin of -1656.3% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.
What is Syros Pharmaceut's free cash flow?
Syros Pharmaceut (SYRS) generated -$110.0M in free cash flow during fiscal year 2023. This represents a 11.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Syros Pharmaceut's operating cash flow?
Syros Pharmaceut (SYRS) generated -$109.7M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Syros Pharmaceut's total assets?
Syros Pharmaceut (SYRS) had $168.2M in total assets as of fiscal year 2023, including both current and long-term assets.
What are Syros Pharmaceut's capital expenditures?
Syros Pharmaceut (SYRS) invested $272K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does Syros Pharmaceut spend on research and development?
Syros Pharmaceut (SYRS) invested $108.2M in research and development during fiscal year 2023.
How many shares does Syros Pharmaceut have outstanding?
Syros Pharmaceut (SYRS) had 26M shares outstanding as of fiscal year 2023.
What is Syros Pharmaceut's current ratio?
Syros Pharmaceut (SYRS) had a current ratio of 3.95 as of fiscal year 2023, which is generally considered healthy.
What is Syros Pharmaceut's debt-to-equity ratio?
Syros Pharmaceut (SYRS) had a debt-to-equity ratio of 2.07 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Syros Pharmaceut's return on assets (ROA)?
Syros Pharmaceut (SYRS) had a return on assets of -97.9% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Syros Pharmaceut's cash runway?
Based on fiscal year 2023 data, Syros Pharmaceut (SYRS) had $139.5M in cash against an annual operating cash burn of $109.7M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Syros Pharmaceut's Piotroski F-Score?
Syros Pharmaceut (SYRS) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Syros Pharmaceut's earnings high quality?
Syros Pharmaceut (SYRS) has an earnings quality ratio of 0.67x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Syros Pharmaceut cover its interest payments?
Syros Pharmaceut (SYRS) has an interest coverage ratio of -25.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Syros Pharmaceut?
Syros Pharmaceut (SYRS) scores 27 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.